Kalaris Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell KLRS and other ETFs, options, and stocks.

About KLRS

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. 

CEO
Andrew Oxtoby
CEOAndrew Oxtoby
Employees
6
Employees6
Headquarters
Berkeley Heights, New Jersey
HeadquartersBerkeley Heights, New Jersey
Founded
Founded
Employees
6
Employees6

KLRS Key Statistics

Market cap
173.00M
Market cap173.00M
Price-Earnings ratio
-1.23
Price-Earnings ratio-1.23
Dividend yield
Dividend yield
Average volume
57.75K
Average volume57.75K
High today
$9.31
High today$9.31
Low today
$8.85
Low today$8.85
Open price
$9.31
Open price$9.31
Volume
26.14K
Volume26.14K
52 Week high
$12.90
52 Week high$12.90
52 Week low
$2.14
52 Week low$2.14

Stock Snapshot

Kalaris Therapeutics(KLRS) stock is priced at $9.25, giving the company a market capitalization of 173M. It carries a P/E multiple of -1.23.

On 2026-03-05, Kalaris Therapeutics(KLRS) stock moved within a range of $8.85 to $9.31. With shares now at $9.25, the stock is trading +4.5% above its intraday low and -0.6% below the session's peak.

Trading volume for Kalaris Therapeutics(KLRS) stock has reached 26.14K, versus its average volume of 57.75K.

The stock's 52-week range extends from a low of $2.14 to a high of $12.90.

The stock's 52-week range extends from a low of $2.14 to a high of $12.90.

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

People also own

Based on the portfolios of people who own KLRS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.